Monane M, Maraganore DM, Carlile RM, Johnson KG, Merrill DA, Gitelman DR, Sharlin KS, VandeVrede LA, George KK, Wang J, et al. Clinical Utility of an Alzheimer's Disease Blood Test Among Cognitively Impaired.
Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study. Diagnostics. 2025;15(2):167. https://doi.org/10.3390/diagnostics15020167

Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512–527. PMID: 37459141.

Monane M, Johnson KG, Snider BJ, Turner RS, Drake JD, Maraganore DM, Bicksel JL, Jacobs DH, Ortega JL, Henderson J, Jiang Y, Huang S, Coppinger J, Fogelman I, West T, Braunstein JB. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Ann Clin Transl Neurol.

2023;10(10):1738–1748. PMID: 37550958.

Bar-Or A, Wiendl H, Montalban X, et al. (including Sharlin K). Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910–924. PMID: 34605319.

Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–557. PMID: 32757523.

Bredesen DE, Sharlin KS, Jenkins D, et al. Reversal of Cognitive Decline: 100 Patients. J Alzheimer's Dis Parkinsonism. 2018;8(5):450.

Sharlin, K.S. & Warner, J.S. Case histories from The Vanderbilt Headache Clinic. Headache Quarterly - Current Treatment and Research. 1997;8(3):252–254.

Sharlin KS, Heath GW, Ford ES, Welty TK. Hypertension and blood pressure awareness among American Indians of the northern plains. Ethn Dis. 1993;3(4):337–343.

Sharlin KS, Beazley MA. Sickle cell trait as a cause of stroke in a 73-year-old man: Implications for primary and secondary prevention. Journal of Stroke & Cerebrovascular Diseases. 1999;8(4):271.